Eriksson, Hanna
Karolinska University Hospital · Karolinska Institutet
3 papers on CoChatORCID 0000-0001-6728-5344
Most cited papers
- Verified
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 537
- Verified
Human-AI interaction in skin cancer diagnosis: a systematic review and meta-analysis
Krakowski, I., Kim, J., Cai, Z. R., Daneshjou, R., Lapins, J., Eriksson, H., Lykou, A., & Linos, E. (2024) · npj Digital Medicine
Cutaneous Melanoma Detection and ManagementAI in cancer detection
Cited by 87
- Verified
18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
Rozeman, E. A., Menzies, A. M., Krijgsman, O., Hoefsmit, E. P., van de Wiel, B. A., Sikorska, K., Van, T. M., Eriksson, H., Bierman, C., Gonzalez, M., et al. (2019) · Annals of Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free